What Happens After You Submit a 15‑Day Adverse Event Report to the FDA for a Dietary Supplement

Many dietary supplement companies approach 15‑day adverse event reporting with hesitation. The concern sometimes surrounds the actual process of submitting a report, but most often, it’s about what happens afterward. Companies may fear that submitting a serious adverse event report places a company on FDA’s radar in a way that leads to enforcement, scrutiny, or escalation. That fear often delays reporting or leads teams to debate whether a report is truly required. Over time, this hesitation can become part of company culture and potentially lead to non-compliance with dietary supplement adverse event reporting requirements. 

Statutory Basis for 15‑Day Reporting 

Under the Dietary Supplement and Nonprescription Drug Consumer Protection Act, dietary supplement manufacturers, packers, and distributors are required to submit a report to FDA within 15 business days after receiving information about a serious adverse event. A serious adverse event includes outcomes such as death, life‑threatening experiences, inpatient hospitalization, significant disability, congenital anomalies, or events that require medical or surgical intervention to prevent those outcomes, as defined under 21 U.S.C. § 379aa‑1. 

The 15‑business‑day timeline exists to support safety signal detection and public health surveillance. It was not designed as a punitive mechanism. FDA relies on timely reporting to identify trends across products, ingredients, and categories, particularly when similar events emerge across multiple sources. 

The MedWatch Form used for mandatory dietary supplement reporting includes language clarifying that submission of a report does not constitute an admission that the product caused or contributed to the event. This distinction exists because FDA’s safety systems are built around association rather than causation. A report reflects that an event occurred in temporal association with product use, not that the product was determined to be responsible. 

How FDA Processes 15‑Day Reports 

Once a 15‑day report is submitted, it is routed within FDA to the Center for Food Safety and Applied Nutrition, including the Office of Dietary Supplement Programs. Reports are entered into FDA’s adverse event databases and used for signal detection and trend analysis. In most cases, no follow‑up action occurs and the majority of reports do not trigger contact with the company, inspection activity, or enforcement. 

When FDA Looks More Closely 

Repeated reports describing similar serious outcomes, clear clustering around specific ingredients, or evidence suggesting adulteration or undeclared drug ingredients can prompt additional review. When that happens, the FDA may evaluate whether the company has a functioning safety system capable of recognizing, documenting, and reporting adverse events consistently. 

Why Failure to Report Carries Greater Risk 

Failure to report carries a higher regulatory risk than reporting. Adverse event reporting is a statutory requirement, and FDA routinely reviews adverse event files during inspections. Failure to report and incomplete reporting have been cited in warning letters and inspection observations. In those cases, the issues typically stem from inadequate complaint reporting processes or improper understanding of reporting requirements. 

Transparency and Public Availability of Data 

Transparency is also part of the FDA’s approach. Dietary supplement adverse event data are made publicly available through the Center for Food Safety and Applied Nutrition Adverse Event Reporting System. This data set includes both voluntary and mandatory reports. It does not establish causation, and it does not include sales volume or exposure data. The purpose of this public dashboard is transparency and public health monitoring. 

How FDA Interprets Consistent Reporting 

From a regulatory perspective, consistent reporting demonstrates competence. It reveals that a company understands its obligations under DSHEA, maintains safety awareness, and participates in the broader public health surveillance system FDA relies on. Historically, FDA views companies with documented, timely reporting practices as lower risk than those with little or no reporting history. 

Practical Takeaways for Supplement Brands 

For supplement brands, the practical takeaway is straightforward. Reporting does not equal admission of fault and it does not automatically lead to enforcement. Reporting fulfills a legal obligation and reduces regulatory exposure when systems are in place and functioning as expected. 

A documented, timely adverse event reporting process is a protective asset. It reflects preparedness, not vulnerability. When teams understand what happens after submission, reporting becomes part of responsible supplement brand rather than a source of anxiety. 

Interested in learning about our certification? Click the button below to learn more, claim your spot, or access our free AE intake resource.

Sources

Food and Drug Administration. (2013). Guidance for industry: Questions and answers regarding adverse event reporting and recordkeeping for dietary supplements.

Food and Drug Administration. (2025). Form FDA 3500A: Mandatory reporting.

U.S. Congress. (2026). 21 U.S.C. § 379aa‑1 – Serious adverse event reporting for dietary supplements.

Food and Drug Administration. (2026). Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS).

Natural Products Association. (2026). Adverse event reporting for dietary supplements.

Disclaimer: All information and content found on this website is for educational and informational purposes only and should not be considered medical advice, legal advice, or health advice. Information on this website should not be used as a substitute for medical advice, diagnosis, or treatment from your licensed healthcare professional. Sincerely PharmD LLC and Sincerely PharmD LLC employees and/or writers are not your healthcare provider. Always consult your healthcare provider for diagnosis, treatment, and medical advice prior to making any changes to your healthcare regimen. Do not delay seeking medical advice from your healthcare provider based on information obtained from this website.